Richard Roden, PhD, is a Professor in the Departments of Pathology, Gynecology and Obstetrics, and Oncology at the Johns Hopkins University School of Medicine. He has co-led the Johns Hopkins Kimmel Cancer Center’s Cancer Prevention and Control Program for 10 years. His research focuses on approaches to prevent and treat cervical cancer through the development of novel vaccines and small molecule proteasome inhibitors. Dr. Roden’s team is currently engaged in the early clinical development of a minor capsid antigen L2-based vaccine that is active against all oncogenic types of human papillomavirus (HPV). He is also working on immunotherapy phase I trials to test their potential to treat HPV infections and dysplasia, thereby interrupting progression to cervical cancer.
